Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXSNASDAQ:CDTXNASDAQ:IOBTNASDAQ:SLRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXSAstria Therapeutics$5.04-3.2%$5.59$3.56▼$12.92$287.19M0.68380,450 shs15,162 shsCDTXCidara Therapeutics$21.43-0.2%$21.06$10.14▼$28.42$234.29M0.8974,433 shs16,077 shsIOBTIO Biotech$0.93+0.2%$0.95$0.66▼$1.79$60.94M0.08272,393 shs8,833 shsSLRNAcelyrin$2.11-3.0%$2.47$1.85▼$7.25$214.43M1.121.21 million shs79,738 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXSAstria Therapeutics+0.39%+28.96%-16.64%-29.69%-42.11%CDTXCidara Therapeutics-1.92%+10.49%-2.50%+13.59%+74.78%IOBTIO Biotech-1.83%+7.29%-21.13%-2.35%-36.79%SLRNAcelyrin-3.56%-1.36%-13.55%+9.60%-52.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXSAstria Therapeutics2.4532 of 5 stars3.63.00.00.03.11.70.0CDTXCidara Therapeutics4.0597 of 5 stars4.62.00.04.62.10.80.0IOBTIO Biotech3.0862 of 5 stars3.73.00.00.03.80.81.3SLRNAcelyrin3.4185 of 5 stars3.25.00.00.02.23.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXSAstria Therapeutics 3.29Buy$26.60427.67% UpsideCDTXCidara Therapeutics 3.25Buy$39.1482.65% UpsideIOBTIO Biotech 3.33Buy$9.33909.01% UpsideSLRNAcelyrin 2.40Hold$9.60356.06% UpsideCurrent Analyst Ratings BreakdownLatest IOBT, ATXS, SLRN, and CDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.004/1/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/12/2025ATXSAstria TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$27.00 ➝ $28.003/12/2025CDTXCidara TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/12/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$46.003/12/2025CDTXCidara TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.003/12/2025IOBTIO BiotechPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/11/2025ATXSAstria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/10/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $35.003/7/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.003/5/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXSAstria TherapeuticsN/AN/AN/AN/A$3.33 per shareN/ACDTXCidara Therapeutics$1.28M184.10N/AN/A($1.82) per share-11.77IOBTIO BiotechN/AN/AN/AN/A$2.02 per shareN/ASLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXSAstria Therapeutics-$72.89M-$1.67N/AN/AN/AN/A-43.58%-29.36%5/8/2025 (Estimated)CDTXCidara Therapeutics-$22.93M-$30.09N/AN/AN/A-289.05%-69.64%-33.73%4/28/2025 (Estimated)IOBTIO Biotech-$86.08M-$1.37N/AN/AN/AN/A-86.56%-75.24%5/13/2025 (Estimated)SLRNAcelyrin-$381.64M-$2.50N/AN/AN/AN/A-44.12%-39.02%5/13/2025 (Estimated)Latest IOBT, ATXS, SLRN, and CDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025CDTXCidara Therapeutics-$5.45N/AN/AN/AN/AN/A5/13/2025Q1 2025IOBTIO Biotech-$0.45N/AN/AN/AN/AN/A5/13/2025Q1 2025SLRNAcelyrin-$0.95N/AN/AN/AN/AN/A5/8/2025Q1 2025ATXSAstria Therapeutics-$0.48N/AN/AN/AN/AN/A3/19/2025Q4 2024SLRNAcelyrin-$0.86-$0.79+$0.07-$0.79N/AN/A3/11/2025Q4 2024ATXSAstria Therapeutics-$0.45-$0.44+$0.01-$0.44N/AN/A3/6/2025Q4 2024CDTXCidara Therapeutics-$5.28-$5.38-$0.10-$5.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXSAstria TherapeuticsN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXSAstria TherapeuticsN/A22.3822.38CDTXCidara TherapeuticsN/A3.543.54IOBTIO BiotechN/A5.375.37SLRNAcelyrinN/A7.157.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXSAstria Therapeutics98.98%CDTXCidara Therapeutics35.82%IOBTIO Biotech54.76%SLRNAcelyrin87.31%Insider OwnershipCompanyInsider OwnershipATXSAstria Therapeutics2.90%CDTXCidara Therapeutics7.64%IOBTIO Biotech2.30%SLRNAcelyrin13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXSAstria Therapeutics3056.43 million54.80 millionOptionableCDTXCidara Therapeutics9010.95 million6.51 millionNo DataIOBTIO Biotech3065.88 million64.37 millionNot OptionableSLRNAcelyrin135100.91 million86.68 millionOptionableIOBT, ATXS, SLRN, and CDTX HeadlinesRecent News About These CompaniesAcelyrin, Inc. (NASDAQ:SLRN) Short Interest UpdateApril 21, 2025 | marketbeat.comAlumis and ACELYRIN Announce Amended Merger AgreementApril 21, 2025 | globenewswire.comACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRNApril 16, 2025 | businesswire.comWellington Management Group LLP Buys New Shares in Acelyrin, Inc. (NASDAQ:SLRN)April 16, 2025 | marketbeat.comExodusPoint Capital Management LP Takes $423,000 Position in Acelyrin, Inc. (NASDAQ:SLRN)April 15, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires 391,467 Shares of Acelyrin, Inc. (NASDAQ:SLRN)April 9, 2025 | marketbeat.comAlumis Inc.; ACELYRIN, INC.: Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed MergerApril 5, 2025 | finanznachrichten.deAlumis Inc. and ACELYRIN, INC. File Joint Definitive Proxy Statement for Proposed MergerApril 5, 2025 | finanznachrichten.deSTOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLDMarch 30, 2025 | morningstar.comInsider Selling: Acelyrin, Inc. (NASDAQ:SLRN) Insider Sells 3,913 Shares of StockMarch 20, 2025 | insidertrades.comAcelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comACELYRIN Adopts Limited-Duration Stockholder Rights PlanMarch 13, 2025 | globenewswire.comAcelyrin: Potential Buyout Led By Concentra BiosciencesMarch 12, 2025 | seekingalpha.comIs Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?March 7, 2025 | insidermonkey.comACELYRIN, INC.: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | finanznachrichten.deAcelyrin says Concentra indication not expected to result in superior proposalMarch 4, 2025 | markets.businessinsider.comAcelyrin falls as Acelyrin reaffirms deal commitmentMarch 4, 2025 | msn.comAcelyrin, Alumis reaffirm strategic, financial rationale of proposed mergerMarch 4, 2025 | markets.businessinsider.comACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | globenewswire.comACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis MergerMarch 4, 2025 | globenewswire.comAcelyrin Stock Jumps on Concentra Acquisition InterestFebruary 21, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOBT, ATXS, SLRN, and CDTX Company DescriptionsAstria Therapeutics NASDAQ:ATXS$5.04 -0.17 (-3.24%) As of 10:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Cidara Therapeutics NASDAQ:CDTX$21.43 -0.05 (-0.23%) As of 10:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.IO Biotech NASDAQ:IOBT$0.92 +0.00 (+0.24%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Acelyrin NASDAQ:SLRN$2.10 -0.07 (-3.00%) As of 10:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Boeing: Turbulence Is Minimal Even If China Stops Buying Planes Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
